Ceryvyn Therapeutics Limited
CYVNY
$0.02
-$0.01-35.00%
OTC PK
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -3.26M | -3.25M | 111.55M | 111.19M | -16.02M |
| Total Depreciation and Amortization | -- | -- | -- | -- | 44.80K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 3.55M | 3.54M | -114.80M | -114.43M | -19.74M |
| Change in Net Operating Assets | -1.19M | -1.18M | -- | -- | -6.82M |
| Cash from Operations | -891.10K | -887.60K | -3.25M | -3.24M | -42.53M |
| Capital Expenditure | -- | -- | -- | -- | 0.00 |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | 0.00 |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 0.00 | 0.00 | -15.44M | -15.44M | -27.50K |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -5.10M |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 0.00 | 0.00 | -10.14M | -10.10M | -3.28M |
| Foreign Exchange rate Adjustments | -192.90K | -192.10K | 6.90K | 6.90K | 1.40M |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -1.08M | -1.08M | -13.38M | -13.34M | -44.42M |